Applied Therapeutics Reports Biomarker Data from Pilot Trial of AT-007 in SORD Deficiency
Neurology, NEW, MD, Research, Peripheral nervous system, Diagnosis, University, Blood, Disease, Industry, Vii, Diabetic cardiomyopathy, CNS, Twitter, Patient, Ix, Private Securities Litigation Reform Act, Hereditary neuropathy with liability to pressure palsy, Applied psychology, Neuromuscular medicine, Xi, U.S. Securities and Exchange Commission, Disability, ID, Eye, Diabetic retinopathy, Government, Ribosomal s6 kinase, Sorbitol, Forward-looking statement, Patent, Intention, COVID-19, Lists of diseases, Investor relations, Metabolism, Nasdaq, ARI, Therapy, PMM2-CDG, Division, Motor neuron, Central nervous system, GLOBE, Doctor of Philosophy, Heart, Pharmaceutical industry
Monday, October 25, 2021 - 12:00pm
NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported biomarker data from a pilot trial of AT-007 in patients with SORD Deficiency.
Key Points:
- Sorbitol Dehydrogenase Deficiency (SORD Deficiency) is a rare, progressive, debilitating hereditary neuropathy that affects peripheral nerves and motor neurons.
- Patients with SORD Deficiency have 100 times higher sorbitol concentration in their blood compared with unaffected individuals.
- In a pilot open-label study in 8 SORD Deficiency patients, AT-007 reduced blood sorbitol levels by approximately 66% from baseline through 30 days of treatment.
- Applied Therapeutics will host a conference call today, Monday, October 25, 2021, at 8:30 a.m. Eastern Time, to discuss data from a pilot trial of AT-007 in SORD deficiency.